In last trading session, Denali Therapeutics Inc (NASDAQ:DNLI) saw 0.99 million shares changing hands with its beta currently measuring 1.34. Company’s recent per share price level of $14.16 trading at $0.2 or 1.43% at ring of the bell on the day assigns it a market valuation of $2.06B. That closing price of DNLI’s stock is at a discount of -135.38% from its 52-week high price of $33.33 and is indicating a premium of 25.35% from its 52-week low price of $10.57.
For Denali Therapeutics Inc (DNLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.05. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Upright in the green during last session for gaining 1.43%, in the last five days DNLI remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $14.16 price level, adding 9.0% to its value on the day. Denali Therapeutics Inc’s shares saw a change of -30.52% in year-to-date performance and have moved -1.87% in past 5-day. Denali Therapeutics Inc (NASDAQ:DNLI) showed a performance of 7.52% in past 30-days.
Wall Street analysts have assigned a consensus price target of 32 to the stock, which implies a rise of 55.75% to its current value. Analysts have been projecting 32 as a low price target for the stock while placing it at a high target of 32. It follows that stock’s current price would drop -125.99% in reaching the projected high whereas dropping to the targeted low would mean a loss of -125.99% for stock’s current value.
Denali Therapeutics Inc (DNLI) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -17.51% while estimates for its earnings growth in next 5 years are of 4.56%.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
BAILLIE GIFFORD & CO is the top institutional holder at DNLI for having 13.76 million shares of worth $319.59 million. And as of 2024-06-30, it was holding 8.1523 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 13.17 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8034 of outstanding shares, having a total worth of $305.91 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025, the former fund manager was holding 7.97 shares of worth $112.88 million or 5.49% of the total outstanding shares. The later fund manager was in possession of 3.72 shares on Dec 31, 2024, making its stake of worth around $52.69 million in the company or a holder of 2.56% of company’s stock.
